Objective: Examine the possible beneficial effects of early, D-dimer driven anticoagulation in preventing thrombotic complications and improving the overall outcomes of COVID-19 intubated patients. Methods: To address COVID-19 hypercoagulability, we developed a clinical protocol to escalate anticoagulation based on serum D-dimer levels. We retrospectively reviewed all our first 240 intubated patients with COVID-19. Of the 240, 195 were stratified into patients treated based on this protocol (ON-protocol, n = 91) and the control group, patients who received standard thromboprophylaxis (OFF-protocol, n = 104). All patients were admitted to the Stony Brook University Hospital intensive care units (ICUs) between February 7th, 2020 and May 17, 2020 and were otherwise treated in the same manner for all aspects of COVID-19 disease. Results: We found that the overall mortality was significantly lower ON-protocol compared to OFF-protocol (27.47 vs. 58.66%, P < 0.001). Average maximum D-dimer levels were significantly lower in the ON-protocol group (7,553 vs. 12,343 ng/mL), as was serum creatinine (2.2 vs. 2.8 mg/dL). Patients with poorly controlled D-dimer levels had higher rates of kidney dysfunction and mortality. Transfusion requirements and serious bleeding events were similar between groups. To address any possible between-group differences, we performed a propensity-matched analysis of 124 of the subjects (62 matched pairs, ON-protocol and OFF-protocol), which showed similar findings (31 vs. 57% overall mortality in the ON-protocol and OFF-protocol group, respectively). Conclusions: D-dimer-driven anticoagulation appears to be safe in patients with COVID-19 infection and is associated with improved survival. What This Paper Adds: It has been shown that hypercoagulability in patients with severe COVID-19 infection leads to thromboembolic complications and organ dysfunction. Anticoagulation has been variably administered to these patients, but it is unknown whether routine or escalated thromboprophylaxis provides a survival benefit. Our data shows that escalated D-dimer driven anticoagulation is associated with improved organ function and overall survival in intubated COVID-19 ICU patients at our institution. Importantly, we found that timely escalation of this anticoagulation is critical in preventing organ dysfunction and mortality in patients with severe COVID-19 infection.
Objective: Examine the possible beneficial effects of early, D-dimer driven anticoagulation in preventing thrombotic complications and improving the overall outcomes of COVID-19 intubated patients. Methods: To address COVID-19 hypercoagulability, we developed a clinical protocol to escalate anticoagulation based on serum D-dimer levels. We retrospectively reviewed all our first 240 intubated patients with COVID-19. Of the 240, 195 were stratified into patients treated based on this protocol (ON-protocol, n = 91) and the control group, patients who received standard thromboprophylaxis (OFF-protocol, n = 104). All patients were admitted to the Stony Brook University Hospital intensive care units (ICUs) between February 7th, 2020 and May 17, 2020 and were otherwise treated in the same manner for all aspects of COVID-19 disease. Results: We found that the overall mortality was significantly lower ON-protocol compared to OFF-protocol (27.47 vs. 58.66%, P < 0.001). Average maximum D-dimer levels were significantly lower in the ON-protocol group (7,553 vs. 12,343 ng/mL), as was serum creatinine (2.2 vs. 2.8 mg/dL). Patients with poorly controlled D-dimer levels had higher rates of kidney dysfunction and mortality. Transfusion requirements and serious bleeding events were similar between groups. To address any possible between-group differences, we performed a propensity-matched analysis of 124 of the subjects (62 matched pairs, ON-protocol and OFF-protocol), which showed similar findings (31 vs. 57% overall mortality in the ON-protocol and OFF-protocol group, respectively). Conclusions: D-dimer-driven anticoagulation appears to be safe in patients with COVID-19infection and is associated with improved survival. What This Paper Adds: It has been shown that hypercoagulability in patients with severe COVID-19infection leads to thromboembolic complications and organ dysfunction. Anticoagulation has been variably administered to these patients, but it is unknown whether routine or escalated thromboprophylaxis provides a survival benefit. Our data shows that escalated D-dimer driven anticoagulation is associated with improved organ function and overall survival in intubated COVID-19 ICU patients at our institution. Importantly, we found that timely escalation of this anticoagulation is critical in preventing organ dysfunction and mortality in patients with severe COVID-19infection.
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Philip S Wells; David R Anderson; Marc Rodger; Melissa Forgie; Clive Kearon; Jonathan Dreyer; George Kovacs; Michael Mitchell; Bernard Lewandowski; Michael J Kovacs Journal: N Engl J Med Date: 2003-09-25 Impact factor: 91.245
Authors: Ishan Paranjpe; Valentin Fuster; Anuradha Lala; Adam J Russak; Benjamin S Glicksberg; Matthew A Levin; Alexander W Charney; Jagat Narula; Zahi A Fayad; Emilia Bagiella; Shan Zhao; Girish N Nadkarni Journal: J Am Coll Cardiol Date: 2020-05-06 Impact factor: 24.094
Authors: Thomas J Oxley; J Mocco; Shahram Majidi; Christopher P Kellner; Hazem Shoirah; I Paul Singh; Reade A De Leacy; Tomoyoshi Shigematsu; Travis R Ladner; Kurt A Yaeger; Maryna Skliut; Jesse Weinberger; Neha S Dangayach; Joshua B Bederson; Stanley Tuhrim; Johanna T Fifi Journal: N Engl J Med Date: 2020-04-28 Impact factor: 91.245
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944
Authors: Saadia Omer; Mehrunnisa Fatima Gondal; Muhammad Usman; Muhammad Bilal Sarwar; Muhammad Roman; Alam Khan; Nadeem Afzal; Tanveer Ahmed Qaiser; Muhammad Yasir; Faheem Shahzad; Romeeza Tahir; Saima Ayub; Javed Akram; Raja Muhammad Faizan; Muhammad Asif Naveed; Shah Jahan Journal: Front Cell Infect Microbiol Date: 2022-05-26 Impact factor: 6.073
Authors: Panagiotis Volteas; Panagiotis Drakos; Leor N Alkadaa; Nathaniel A Cleri; Anthony A Asencio; Anthony Oganov; Stefanos Giannopoulos; Jordan R Saadon; Charles B Mikell; Jerry A Rubano; Nicos Labropoulos; Apostolos K Tassiopoulos; Sima Mofakham; Mohsen Bannazadeh Journal: J Vasc Surg Venous Lymphat Disord Date: 2022-06-15
Authors: Panagiotis Drakos; Panagiotis Volteas; Nathaniel A Cleri; Leor N Alkadaa; Anthony A Asencio; Anthony Oganov; Aurora Pryor; Mark Talamini; Jerry Rubano; Mohsen Bannazadeh; Charles B Mikell; Konstantinos Spaniolas; Sima Mofakham Journal: J Gastrointest Surg Date: 2021-04-27 Impact factor: 3.452
Authors: Muhammad Aamir Waheed; Khalid Rashid; Tawfik Rajab; Ahmad Rajab; Adnan H Adnan; Harris Fayyaz; Ahmad A Ibad; Rabia Basri; Yahya Khan; Habib I Alhabib; Abdelnaser Elzouki Journal: Saudi Med J Date: 2022-06 Impact factor: 1.422